Patents by Inventor William Robert McDaniel

William Robert McDaniel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10143639
    Abstract: A method of correcting the visible and microscopic signs of Dermatoheliosis (chronic ultraviolet light-damaged human skin) and its various clinical manifestations (wrinkling, sagging, fragility, melasma, Poikiloderma of Civatte, solar lentigines, and senile purpura) and also Androgenetic Alopecia and Seborrheic Keratoses consists of the administration of fatty acid derivatives capable of inhibiting mast cells and the mediators they release that cause local tissue damage. These fatty acid derivatives include palmitoylethanolamide (PEA) and related cannabinomimetic compounds and adelmidrol and related Autacoid Local Injury Antagonist amides (ALIAmides) which are administered orally or applied topically. Adelmidrol, the best absorbed topically, is applied in a concentration of between 1% and 10% by volume, with a preferred concentration of about 5% by volume.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: December 4, 2018
    Inventor: William Robert McDaniel
  • Publication number: 20180271761
    Abstract: A method of correcting the visible and microscopic signs of Dermatoheliosis (chronic ultraviolet light-damaged human skin) and its various clinical manifestations (wrinkling, sagging, fragility, melasma, Poikiloderma of Civatte, solar lentigines, and senile purpura) and also Androgenetic Alopecia and Seborrheic Keratoses consists of the administration of fatty acid derivatives capable of inhibiting mast cells and the mediators they release that cause local tissue damage. These fatty acid derivatives include palmitoylethanolamide (PEA) and related cannabinomimetic compounds and adelmidrol and related Autacoid Local Injury Antagonist amides (ALIAmides) which are administered orally or applied topically. Adelmidrol, the best absorbed topically, is applied in a concentration of between 1% and 10% by volume, with a preferred concentration of about 5% by volume.
    Type: Application
    Filed: March 22, 2017
    Publication date: September 27, 2018
    Inventor: William Robert McDaniel
  • Patent number: 8067470
    Abstract: A preparation for the topical application of linoleic acid to treat male and female androgenetic alopecia, age-related alopecia, and keratosis pilaris contains between about 0.1% and about 10%, preferably between about 1% and about 5%, and specifically about 2% linoleic acid by volume in its carrier vehicle. This acts to correct the local linoleic acid deficiency that exists in the follicles in these conditions and provides linoleic acid to suppress growth of Propionibacterium acnes with resultant reduction in its porphyrin production which in turn reduces microinflammation and altered keratinization that damages follicles and eliminates functioning follicles in alopecia and causes follicle plugging in keratosis pilaris.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: November 29, 2011
    Inventor: William Robert McDaniel
  • Publication number: 20090197954
    Abstract: A preparation for the topical application of linoleic acid to treat male and female androgenetic alopecia, age-related alopecia, and keratosis pilaris contains between about 0.1% and about 10%, preferably between about 1% and about 5%, and specifically about 2% linoleic acid by volume in its carrier vehicle. This acts to correct the local linoleic acid deficiency that exists in the follicles in these conditions and provides linoleic acid to suppress growth of Propionibacterium acnes with resultant reduction in its porphyrin production which in turn reduces microinflammation and altered keratinization that damages follicles and eliminates functioning follicles in alopecia and causes follicle plugging in keratosis pilaris.
    Type: Application
    Filed: February 1, 2008
    Publication date: August 6, 2009
    Inventor: William Robert McDaniel
  • Patent number: 5952372
    Abstract: A method of treating rosacea in humans involving orally-administered or topically-applied ivermectin is disclosed. More specifically, oral ivermectin in a regimen of 200 micrograms per kilogram body weight per dose for 2 or 3 consecutive doses at least 3 and not more than 7 days apart as the preferred regimen or, alternatively, topical ivermectin compounded to a 2% concentration by weight in a cream, lotion, or gel carrier vehicle is administered as an effective treatment for all clinical stages and signs of rosacea in affected persons.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: September 14, 1999
    Inventor: William Robert McDaniel